| Literature DB >> 26633649 |
Katharine M Benedict1, Sheryl P Gow2, Tim A McAllister3, Calvin W Booker4, Sherry J Hannon4, Sylvia L Checkley5, Noelle R Noyes1, Paul S Morley1.
Abstract
The objectives of this study were to estimate the prevalence of antimicrobial resistance (AMR) and to investigate the associations between exposures to antimicrobial drugs (AMDs) and AMR in fecal non-type specific Escherichia coli (NTSEC) recovered from a large population of feedlot cattle. Two-stage random sampling was used to select individually identified cattle for enrollment, which were sampled at arrival and then a second time later in the feeding period. Advanced regression techniques were used to estimate resistance prevalences, and to investigate associations between AMD exposures in enrolled cattle and penmates and AMR identified in NTSEC recovered from the second sample set. Resistance was most commonly detected to tetracycline, streptomycin, and sulfisoxazole, and was rarely identified for critically important AMDs. All cattle were exposed to AMDs in feed, and 45% were treated parenterally. While resistance prevalence generally increased during the feeding period, most AMD exposures were not significantly associated with AMR outcomes. Exposures of enrolled cattle to tetracycline were associated with increased resistance to tetracycline and trimethoprim sulfa, while beta-lactam exposures were associated with decreased likelihood of detecting streptomycin resistance. Pen-level AMD exposure measures were not associated with resistance outcomes. These findings suggest that tetracycline treatment of feedlot cattle can be associated with modest increases in risk for recovery of resistant NTSEC, but the numerous treatments with an advanced macrolide (tulathromycin) were not associated with detectable increases in resistance in NTSEC. All cattle were exposed to in-feed treatments of tetracycline and this could limit the ability to identify the full impact of these exposures, but these exposures varied for enrolled cattle varied, providing an opportunity to evaluate a dose response. While AMD exposures were not associated with detectably increased risks for resistance to critically important AMDs, rare resistance outcomes and infrequent exposure to other important AMDs (e.g., cephalosporins) limited our ability to rigorously investigate questions regarding factors that can influence resistance to these important AMDs.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26633649 PMCID: PMC4669080 DOI: 10.1371/journal.pone.0143995
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Selection of study pens, individuals and E. coli isolates at arrival and second sampling.
Fig 2Prevalence of resistance in non-type-specific E. coli recovered from feedlot cattle, by sampling date.
Marginal (adjusted) means estimates of the prevalence of resistance to various antimicrobial drugs among non-type specific E. coli isolates obtained from individual fecal samples at the first and second samplings. These estimates have been adjusted for isolate, individual, and pen effects. Due to a large variation in second sampling relative to days on feed, estimates have been categorized and presented at 33–75 days on feed, 75–120 days on feed, and >120 days on feed. Error bars represent 95% confidence intervals. Dashed lines differentiate which antimicrobial drugs were tested by one or both susceptibility testing methods. Number of isolates in legend indicate how many were tested by each susceptibility test (n = number tested by disk diffusion / number tested by both tests / number tested by broth microdilution). P-values relate to differences in adjusted prevalence among the 4 days-on-feed categories, and were not adjusted for multiple comparisons among AMDs. * = unadjusted prevalence with “plus four 95% confidence interval for a proportion".
Number of antimicrobial drugs to which non-type specific E. coli isolates were resistant.
| Test Method | Number of Resistant Drugs in Phenotype | Percent Resistance (n) | |
|---|---|---|---|
| First Sample Set | Second Sample Set | ||
|
| Pansusceptible | 79.8% (1898) | 21.9% (597) |
| 1 | 11.2% (266) | 41.8% (1138) | |
| 2 | 4.0% (94) | 18.8% (513) | |
| 3 | 3.7% (88) | 10.2% (279) | |
| 4 | 0.9% (22) | 5.0% (135) | |
| 5 | 0.3% (7) | 2.1% (57) | |
| 6 | 0.0% (0) | 0.1% (2) | |
| 7 | 0.0% (0) | 0.04% (1) | |
| 8 | 0.1% (3) | 0.04% (1) | |
| 9 | 0.04% (1) | 0.1% (2) | |
|
| Pansusceptible | 76.5% (1272) | 26.3% (490) |
| 1 | 12.9% (215) | 37.1% (691) | |
| 2 | 3.9% (65) | 16.7% (311) | |
| 3 | 4.8% (80) | 12.8% (239) | |
| 4 | 1.1% (19) | 4.8% (90) | |
| 5 | 0.5% (8) | 1.9% (36) | |
| 6 | 0.2% (3) | 0.2% (4) | |
| 7 | 0.0% (0) | 0.1% (2) | |
| 8 | 0.0% (0) | 0.05% (1) | |
| 9 | 0.1% (1) | 0.0% (0) | |
a Estimates were not adjusted for non-independence between isolates sampled from the same individual and between individuals from the same pen.
b The susceptibility panel evaluated with broth microdilution evaluated 15 drugs (see S2 Table); n = 2379 for the first sample set, and n = 2725 for the second sample set.
c The susceptibility panel evaluated with broth microdilution evaluated 11 drugs (see S3 Table); n = 1663 for the first sample set, and n = 1864 for the second sample set.
Resistance patterns for non-type specific E. coli isolates recovered from the arrival and second sample sets.
| Sample Set and Testing Method | Frequency | Percent of Isolates from Group | Resistance Pattern |
|---|---|---|---|
|
| |||
|
| 1898 | 79.8% | Pansusceptible (i.e., no resistance detected) |
| 249 | 10.5% | Tet | |
| 55 | 2.3% | Sulf-Strep-Tet | |
| 47 | 2.0% | Sulf-Tet | |
| 25 | 1.1% | Strep-Tet | |
| 18 | 0.8% | Chlor-Sulf-Strep-Tet | |
| 17 | 0.7% | Amp-Strep-Tet | |
| 17 | 0.7% | Amp-Tet | |
| 53 | 2.2% | Other Phenotypes | |
|
| |||
|
| 1272 | 76.5% | Pansusceptible (i.e., no resistance detected) |
| 172 | 10.3% | Tet | |
| 53 | 3.2% | Sulf-Strep-Tet | |
| 23 | 1.4% | Sulf-Tet | |
| 18 | 1.1% | Strep-Tet | |
| 17 | 1.0% | Amp | |
| 15 | 0.9% | Amp-Strep-Tet | |
| 15 | 0.9% | Flor-Sulf-Strep-Tet | |
| 12 | 0.7% | Amp-Tet | |
| 9 | 0.5% | Sulf | |
| 57 | 3.4% | Other Phenotypes | |
|
| |||
|
| 597 | 21.9% | Pansusceptible (i.e., no resistance detected) |
| 1130 | 41.5% | Tet | |
| 255 | 9.4% | Sulf-Tet | |
| 183 | 6.7% | Strep-Tet | |
| 178 | 6.5% | Sulf-Strep-Tet | |
| 83 | 3.1% | Chlor-Sulf-Strep-Tet | |
| 55 | 2.0% | Amp-Tet | |
| 34 | 1.3% | Amp-Strep-Tet | |
| 29 | 1.1% | Kan-Sulf-Strep-Tet | |
| 23 | 0.8% | Chlor-Sulf-Tet | |
| 19 | 0.7% | Chlor-Sulf-Strep-TMS-Tet | |
| 15 | 0.6% | Amp-Sulf-Tet | |
| 14 | 0.5% | Nal-Tet | |
| 13 | 0.5% | Amp-Chlor-Sulf-Strep-Tet | |
| 13 | 0.5% | Chlor-Sulf-Strep | |
| 84 | 3.1% | Other Phenotypes | |
|
| |||
|
| 491 | 26.3% | Pansusceptible (i.e., no resistance detected) |
| 675 | 36.2% | Tet | |
| 164 | 8.8% | Sulf-Strep-Tet | |
| 145 | 7.8% | Sulf-Tet | |
| 112 | 6.0% | Strep-Tet | |
| 66 | 3.5% | Sulf-Flor-Strep-Tet | |
| 37 | 2.0% | Amp-Tet | |
| 30 | 1.6% | Amp-Strep-Tet | |
| 16 | 0.9% | Sulf-Flor-Tet | |
| 14 | 0.8% | Sulf-Flor-Strep-TMS-Tet | |
| 10 | 0.5% | Sulf-Neo-Strep-Tet | |
| 9 | 0.5% | TMS-Tet | |
| 95 | 0.4% | Other |
a Estimates were not adjusted for non-independence between isolates sampled from the same individual and between individuals from the same pen.
b Amp = ampicillin; Chlor = chloramphenicol; Flor = florfenicol; Kan = kanamycin; Nal = naladixic acid; Neo = neomycin; Strep = streptomycin; Sulf = sulfamethoxazole; Tet = tetracycline; TMS = trimethoprim-sulfamethoxazole.
c Other phenotypes were those that individually represented <0.5% of isolates.
Exposures to antimicrobial drugs in individual cattle from which NTSEC were recovered for this study (n = 923).
| Antimicrobial Drug Exposure | Days Prior to Second Sample Collection | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Route of Administration | Class | 0 to 3 | 4 to 14 | >14 | Total | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| |||||||||||||
| Beta lactam | 0 | 0.0% | 0 | 2 | 0.2% | 6 | 15 | 1.6% | 35 | 17 | 1.8% | 41 | |
| Macrolide | 0 | 0.0% | 0 | 0 | 0.0% | 0 | 186 | 20.2% | 504 | 186 | 20.2% | 504 | |
| Phenicol | 0 | 0.0% | 0 | 1 | 0.1% | 3 | 13 | 1.4% | 39 | 14 | 1.5% | 42 | |
| Quinolone | 0 | 0.0% | 0 | 0 | 0.0% | 0 | 4 | 0.4% | 12 | 4 | 0.4% | 12 | |
| Sulfonamide | 0 | 0.0% | 0 | 0 | 0.0% | 0 | 3 | 0.3% | 9 | 3 | 0.3% | 9 | |
| Tetracycline | 0 | 0.0% | 0 | 0 | 0.0% | 0 | 258 | 28.0% | 751 | 258 | 28.0% | 751 | |
|
| |||||||||||||
| Macrolide | 30 | 3.3% | 1.1 | 21 | 2.3% | 2 | 91 | 9.9% | 9.8 | 102 | 11.1% | 12.8 | |
| Tetracycline | 894 | 96.9% | 146.8 | 910 | 98.6% | 553 | 923 | 100.0% | 7751.5 | 923 | 100.0% | 8451.5 | |
NTSEC = non-type-specific E. coli
a Number of enrolled cattle that received AMDs among those from which NTSEC were recovered and used in these analyses
b Percent of exposed cattle relative to the number of enrolled cattle from which NTSEC were recovered and used in these analyses (n = 923)
c Sum of ADDs administered to enrolled cattle. ADD = animal defined dose, or the amount of drug needed to achieve therapeutic concentrations in target tissues for one day.
Pen-level exposures to antimicrobial drugs for groups which housed cattle that were used (n = 215 pens).
| Antimicrobial Drug Exposures | Pens Exposed | Averages for Cattle Housed in Exposed Pens | |||
|---|---|---|---|---|---|
| Route of Administration | Class | n | % | Average ADD per Animal | Average ADD Per Animal-Day |
|
| |||||
| Beta lactam | 153 | 71.2% | 0.0573 | 0.0006 | |
| Macrolide | 131 | 60.9% | 0.7199 | 0.0075 | |
| Phenicol | 65 | 30.2% | 0.0713 | 0.0007 | |
| Quinolone | 76 | 35.3% | 0.0421 | 0.0004 | |
| Sulfonamide | 117 | 54.4% | 0.036 | 0.0004 | |
| Tetracycline | 153 | 71.2% | 1.1048 | 0.0116 | |
|
| |||||
| Macrolide | 34 | 15.8% | 0.0812 | 0.0009 | |
| Tetracycline | 215 | 100.0% | 9.1825 | 0.0962 | |
a Number of pens where enrolled cattle (n = 923 from which NTSEC were recovered and used in analyses) received antimicrobial drugs.
b Percent of pens relative to the total number that housed cattle from which NTSEC were recovered and used in analyses (n = 215).
c Pen-level average of the Animal Defined Doses (ADDs) of antimicrobial drugs administered to all cattle in housed in pens (total cattle n = 42,729 from n = 215 pens).
d Pen-level average of the ADDs received per animal, per day prior to the date when the second sample set was collected for a pen. Overall, the average time from arrival until sample collection was 95.5 days.
Final multivariable logistic models of associations between antimicrobial drugs and antimicrobial resistance.
| Resistance Outcome Variable | Exposure Variable | Odds Ratio |
|
|---|---|---|---|
| Tetracycline | Individual Parenteral Tetracycline | 1.32 (1.01–1.73) | 0.04 |
| Individual In Feed Tetracycline | 1.18 (1.03–1.35) | 0.01 | |
| Streptomycin | Individual Parenteral Beta lactam | 0.32 (0.08–1.25) | 0.01 |
| Trimethoprim-Sulfamethoxazole | Individual Parenteral Tetracycline | 2.59 (1.72–3.89) | 0.001 |
Population-averaged odds ratios and 95% confidence intervals (95%CI) are presented relative to an exposure of 3 ADD (animal defined daily dose) treatment of parenteral antimicrobials or a 7 ADD exposure to in-feed antimicrobials.
a Results of logistic regression modeling using generalized estimating equations (GEE) and alternating logistic regression for the outcomes of tetracycline and streptomycin resistance; controls for 1 level of clustering (individuals) with 1 subcluster (isolates). The outcome of trimethoprim-sulfamethoxazole resistance was analyzed using regular GEE regression models controlling for 1 level of clustering (isolates). Feedlot ID was controlled as a fixed effect in all models.
b Model included the variable for individual exposures to parenteral sulfonamides as a confounding variable (P = 0.19).
Dependence at different levels of clustering for NTSEC isolates in the second sample set as estimated using alternating logistic regression .
| Antimicrobial Drug Resistance | n | Resistance Prevalence | (95%CI) | Dependence in Resistance Results | |||||
|---|---|---|---|---|---|---|---|---|---|
| Pen | Individual | Isolate | |||||||
|
|
|
|
|
|
| ||||
| Amoxicillin-Clavulanate | 8631 | 0.3% | (0.1–0.5%) | 9.1 | (4.5–18.4) | NE | NE | ||
| Ampicillin | 8631 | 4.7% | (4–5.4%) | 2.9 | (1.8–4.6) | NE | NE | ||
| Cefoxitin | 5104 | 0.2% | (0.1–0.4%) | 10.2 | (4.8–21.8) | NE | — | ||
| Ceftiofur | 8631 | 0.3% | (0.1–0.5%) | 5.6 | (1.4–22.7) | NE | NE | ||
| Chloramphenicol | 5104 | 4.4% | (2.4–7.8%) | 3.6 | (3.2–4.1) | NE | — | ||
| Florfenicol | 3527 | 5.0% | (3.1–8.1%) | 3.0 | (2.7–3.4) | NE | — | ||
| Neomycin | 3527 | 1.0% | (0.5–1.8%) | 2.4 | (1.2–4.8) | NE | — | ||
| Streptomycin | 8631 | 17.5% | (14.3–21.4%) | 1.9 | (1.6–2.2) | 10.9 | (9.3–12.7) | 65.2 | (61.1–69.7) |
| Sulfisoxazole | 8631 | 19.5% | (15.6–24.5%) | 1.7 | (1.3–2.1) | 11.7 | (10–13.8) | 243.7 | (141.1–421.1) |
| Tetracycline | 8631 | NE | 2.0 | (1.8–2.1) | 9.8 | (8–12) | 138.3 | (93.7–204.3) | |
a Pairwise odds ratios (PWOR) and 95% confidence intervals (95%CI) of null models are presented for each hierarchical level.
b The prevalence of resistance to the 9 other antimicrobial drugs was too low to allow estimation of PWOR for clustering.
c Numbers of susceptibility tests performed using either broth microdilution or disk diffusion. Some isolates were tested using both methods.
d The adjusted prevalence is averaged across all days-on-feed categories (arrival, 33–75, 76–120, and >120 DOF) and controls for the population hierarchy at different indicated levels within a feedlot.
e PWOR and 95%CI regarding the likelihood of obtaining the same results (resistant or non-resistant) for two tests randomly selected from the same pen, from the same individual animal, or for repeated testing of the same isolate.
f Not estimable because of low resistance prevalence.
g Susceptibility was only tested by disk diffusion.
h Susceptibility was only tested by broth microdilution.
NE = not estimable
Multivariate correlation between resistance outcomes.
Pairwise correlation between 2 antimicrobial resistance outcomes obtained from a multivariate regression model including resistances to tetracycline, streptomycin, sulfisoxazole, ampicillin, and chloramphenicol.
| Antimicrobial Drug Resistance Combination | Correlation | Standard Error |
| |
|---|---|---|---|---|
| Streptomycin | Sulfisoxazole | 0.50 | 0.02 | <0.0001 |
| Tetracycline | Sulfisoxazole | 0.34 | 0.03 | <0.0001 |
| Sulfisoxazole | Chloramphenicol | 0.33 | 0.03 | <0.0001 |
| Tetracycline | Streptomycin | 0.33 | 0.03 | <0.0001 |
| Streptomycin | Chloramphenicol | 0.27 | 0.03 | <0.0001 |
| Streptomycin | Ampicillin | 0.16 | 0.03 | <0.0001 |
| Tetracycline | Chloramphenicol | 0.12 | 0.03 | 0.0001 |
| Tetracycline | Ampicillin | 0.09 | 0.03 | 0.01 |
| Ampicillin | Chloramphenicol | 0.06 | 0.03 | 0.06 |
| Sulfisoxazole | Ampicillin | 0.05 | 0.03 | 0.15 |